Marcela V. Maus, M.D.,Ph.D.
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Marcela V. Maus, M.D.,Ph.D. sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).
Marcela V. Maus, M.D.,Ph.D.: 8 sponsored US clinical trials, 6 recruiting.
Marcela V. Maus, M.D.,Ph.D. sponsors 8 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is High Grade B-Cell Lymphoma, with 2 trials.
Upper-quartile sponsor footprint
Marcela V. Maus, M.D.,Ph.D. sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
8 total, page 1 of 1
CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis
NCT07388277
Emapalumab Prevention of CAR-T Cell Associated Toxicities
NCT06550141
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
NCT06026319
Long-term Follow-up of Subjects Treated With CAR T Cells
NCT05024175
CARv3-TEAM-E T Cells in Glioblastoma
NCT05660369
TriPRIL CAR T Cells in Multiple Myeloma
NCT05020444
A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity
NCT04150913
CAR-37 T Cells in Hematologic Malignancies
NCT04136275
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 2 |
What is open in the Marcela V. Maus, M.D.,Ph.D. pipeline
6 recruiting of 8 indexed (75% open); 2 completed (25%).
Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).
Top condition: High Grade B-Cell Lymphoma (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Marcela V. Maus, M.D.,Ph.D.: open-pipeline peers nationwide
Peers matched on 8 registered trials and 75% open enrollment, not the therapeutic-area sidebar.
Marcela V. Maus, M.D.,Ph.D. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 8 trials (± recruiting share)
- AB Science · 8 trials · 25% recruiting
- Abbott Point of Care · 8 trials · 25% recruiting
- Abeona Therapeutics · 8 trials · 0% recruiting
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 8 trials · 38% recruiting
Sponsors near 75% open enrollment (± trial volume)
- A2 Biotherapeutics · 75% recruiting · 4 trials
- Acepodia Biotech · 75% recruiting · 4 trials
- American Laboratory Products Company · 75% recruiting · 4 trials
- Amryt Pharma · 75% recruiting · 4 trials
Related
What to do with this Marcela V. Maus, M.D.,Ph.D. page
8 registered trials is a research-attention snapshot, not an endorsement of Marcela V. Maus, M.D.,Ph.D. or any single study.
- 6 of Marcela V. Maus, M.D.,Ph.D.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- High Grade B-Cell Lymphoma is the condition Marcela V. Maus, M.D.,Ph.D. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See High Grade B-Cell Lymphoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Marcela V. Maus, M.D.,Ph.D. pipeline card: 8 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.